More recently, the IMBrave150 trial compared the combination of bevacizumab and atezolizumab (anti-programmed cell death ligand 1 (anti-PD-L1)) with sorafenib in unresectable HCC, and showed that the combination was associated with better clinical outcomes, including PFS (6.8 months vs. 4.3 months) and OS (not reached vs. 13.2 months) [10]. This evidence concerns the gene CD274 and hepatocellular carcinoma.